Your quote: "Pfizer wines and dines the docs along with the best of them. It also will help of course to have a vastly superior product in Torcetrapib/Lipitor." You can say that again! All the wining, dining, employee cutbacks, stock repurchasing, and other iniatives of the company to look good in the eyes of the investors and analysts will not disguise real or perceived weaknesses in the company's pipeline. That is really where the real action is in so far as how PFE is perceived by the analysts and investors. This issue takes center stage in tomorrow's meeting of your CEO buddy Kindler with the investors. Is he going to do us proud or is he going to blow a second chance just like he did in the Oct. 19 quarterly earnings report meeting with the analysts? It is anybody's guess. I hope he does us all proud since you and I in particular are rather heavy PFE investors.